ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Identification of the Sequence Specificity in C-Src SH3 Required for Binding to Integrin Β3 as a Novel Anti-Thrombotic Target without Compromising Primary Hemostasis

J. Mao1, Y. Wang1, B. Xiao1, Z. Long1, K. Zhu2, J. Liu2, Z. Ruan1, W. Xi1, C. Luo2, X. Xi1

1Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Shanghai, China, 2Chinese Academy of Sciences, Shanghai Institute of Materia Medica, Shanghai, China

Abstract Number: PB1459

Meeting: ISTH 2020 Congress

Theme: Platelet Disorders and von Willebrand Disease » Platelet Antagonists and Novel Therapeutics

Background: Targeting platelet outside-in signaling inhibits thrombosis without compromising hemostasis. We previously showed that blockade of outside-in signaling was achieved by targeting the interaction of integrin β3 with c-Src. The c-Src SH3 is known to bind the canonical proline-rich motif and thereby regulates many biological processes. Therefore, it is essential to identify the sequences within SH3 responsible for the β3/SH3 interaction so that one may tell it apart from the canonical binding in the context of targeting strategy.

Aims: To identify the targets of integrin β3 in c-Src SH3 and evaluate their roles in anti-thrombosis and hemostasis in transgenic mouse model.

Methods: A synthetic small molecule known to interrupt the β3/SH3 interaction was used to mimic the β3 cytoplasmic domain. NMR, chemical shift perturbation and SPR were applied to identify the targets. Co-IP was assayed for β3/Src interaction and platelet aggregation, adhesion and spreading on immobilized fibrinogen for platelet function. The transgenic mouse model was generated and the FeCl3-induced carotid arterial thrombus formation and tail bleeding time assay were performed.

Results: The RT-loop of SH3, especially E97, was critically required for binding the small molecule and the β3 cytoplasmic domain but not necessarily for binding the canonical PXXP-containing RLP1 peptide and for the c-Src kinase activity that were primarily dependent upon the amino acids in the n-Src loop (Fig.1). The c-SrcE97A mouse model was established. The β3/Src interaction in c-SrcE97A mice was interrupted and the platelet function was significantly diminished. Notably, c-SrcE97A mice exhibited a reduced thrombotic potential in the FeCl3-induced thrombosis model with a normal hemostasis in the tail-bleeding assay (Fig.2).

Conclusions: We identified that E97 in the RT-loop of c-Src SH3 was critical for β3 binding but was unlikely to contribute significantly to the canonical binding and kinase activity. The sequences around E97 may thus serve as potential anti-thrombotic targets.


[Identification of the target sites of integrin β3 in c-Src SH3]


[Effects of the c-SrcE97A mutation on the β3/Src interaction, platelet function, thrombus formation and tail bleeding in transgenic mice]

To cite this abstract in AMA style:

Mao J, Wang Y, Xiao B, Long Z, Zhu K, Liu J, Ruan Z, Xi W, Luo C, Xi X. Identification of the Sequence Specificity in C-Src SH3 Required for Binding to Integrin Β3 as a Novel Anti-Thrombotic Target without Compromising Primary Hemostasis [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/identification-of-the-sequence-specificity-in-c-src-sh3-required-for-binding-to-integrin-%ce%b23-as-a-novel-anti-thrombotic-target-without-compromising-primary-hemostasis/. Accessed September 21, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/identification-of-the-sequence-specificity-in-c-src-sh3-required-for-binding-to-integrin-%ce%b23-as-a-novel-anti-thrombotic-target-without-compromising-primary-hemostasis/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley